Tempus AI (NASDAQ:TEM) has been on fire, drawing massive interest from institutional investors in the fourth quarter of 2024 as big funds piled into the AI-powered precision medicine company.
Since going public in June 2024, Tempus has quickly become a favorite among investors. The number of institutional filings jumped from 89 to 174 in just three quarters, and the total number of shares heldexcluding optionshas climbed significantly.
Cathie Wood's ARK Investment Management was one of the most aggressive buyers, boosting its stake by 132% from Q3 and an eye-popping 956% from Q2, bringing its holdings to $186.3 million. JPMorgan Chase (NYSE:JPM) made an even bigger move, adding 1,650,096 sharesa staggering 43424% increase in just one quarter. UBS Group (NYSE:UBS) wasn't far behind, increasing its stake by 6524% (786,025 shares).
And they weren't the only ones. Barclays (NYSE:BCS) raised its position by 3675%, while Goldman Sachs (NYSE:GS) and Morgan Stanley (NYSE:MS) increased theirs by 129% and 40%, respectively. Meanwhile, BlackRock (NYSE:BLK), Bank of New York Mellon (NYSE:BK), and Ken Griffin's Citadel Advisors all took fresh positions, joining 70 other funds in making a big bet on Tempus AI.
This article first appeared on GuruFocus.免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。